Insmed Incorporated (NASDAQ:INSM) Shares Sold by SG Americas Securities LLC

SG Americas Securities LLC decreased its position in shares of Insmed Incorporated (NASDAQ:INSM) by 31.0% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,813 shares of the biopharmaceutical company’s stock after selling 1,715 shares during the period. SG Americas Securities LLC’s holdings in Insmed were worth $118,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the company. Walleye Capital LLC acquired a new stake in Insmed in the 3rd quarter valued at about $1,820,000. Graham Capital Management L.P. raised its position in Insmed by 352.5% in the 3rd quarter. Graham Capital Management L.P. now owns 43,605 shares of the biopharmaceutical company’s stock valued at $1,101,000 after purchasing an additional 33,969 shares in the last quarter. Vanguard Group Inc. raised its position in Insmed by 7.7% in the 3rd quarter. Vanguard Group Inc. now owns 14,345,512 shares of the biopharmaceutical company’s stock valued at $362,224,000 after purchasing an additional 1,024,956 shares in the last quarter. Trexquant Investment LP raised its position in Insmed by 898.8% in the 3rd quarter. Trexquant Investment LP now owns 294,993 shares of the biopharmaceutical company’s stock valued at $7,449,000 after purchasing an additional 265,457 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. raised its position in Insmed by 8.8% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,099,807 shares of the biopharmaceutical company’s stock valued at $27,770,000 after purchasing an additional 88,589 shares in the last quarter.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on INSM shares. Guggenheim increased their price target on Insmed from $52.00 to $54.00 and gave the company a “buy” rating in a research report on Tuesday, February 27th. UBS Group assumed coverage on Insmed in a report on Tuesday, February 27th. They issued a “buy” rating and a $46.00 price objective on the stock. StockNews.com upgraded Insmed from a “sell” rating to a “hold” rating in a report on Wednesday, February 28th. Wolfe Research assumed coverage on Insmed in a report on Thursday, February 15th. They issued an “outperform” rating and a $42.00 price objective on the stock. Finally, Barclays increased their price objective on Insmed from $37.00 to $40.00 and gave the company an “overweight” rating in a report on Thursday, April 11th. One equities research analyst has rated the stock with a hold rating and eleven have given a buy rating to the company. According to data from MarketBeat, Insmed presently has a consensus rating of “Moderate Buy” and a consensus price target of $44.64.

Insmed Stock Down 5.3 %

NASDAQ:INSM opened at $24.80 on Friday. The stock’s 50 day moving average price is $27.53 and its 200 day moving average price is $27.03. The company has a market capitalization of $3.68 billion, a PE ratio of -4.64 and a beta of 0.92. Insmed Incorporated has a 52-week low of $17.41 and a 52-week high of $32.00.

Insmed (NASDAQ:INSM) last released its quarterly earnings results on Thursday, February 22nd. The biopharmaceutical company reported ($1.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.13) by ($0.15). The company had revenue of $83.70 million during the quarter, compared to analysts’ expectations of $82.15 million. During the same quarter in the previous year, the company earned ($1.20) EPS. The firm’s revenue was up 41.1% compared to the same quarter last year. As a group, sell-side analysts anticipate that Insmed Incorporated will post -4.65 EPS for the current fiscal year.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.